Kornimate/medical-research-clean huggingface dataset:
hormones and reduction in co-users of marijuana and nicotine

Conditions: Marijuana Dependence

Summary: the purpose of this study is to examine the role of progesterone (a naturally occurring hormone found in both men and women) on reducing marijuana use. the investigators will see if progesterone effects impulsivity, withdrawal, mood and stress during marijuana cessation.

this double-blind, randomized pilot clinical trial will prescreen an estimated 250 potential subjects, consent and further evaluate approximately 100 potential subjects, and ultimately enroll 70 subjects to ensure 40 subjects will provide a primary marijuana reduction outcome measure at four weeks post quit date. subjects will be stratified by sex then randomized to one of two treatment groups (n=20 per drug group, 50% female): progesterone (pro; 200mg 2x/day) or placebo (pbo). telephone screening and visit invitation (20 minutes) leads to the consent process and in-person screening including medical-psychiatric evaluation for inclusion/exclusion (two visits, two hours each), then randomization and medication start (7 days), then stable medication (28 days) with medication reduction and final evaluation (7 days).

Eligibility criteria:
inclusion criteria: * males 18-60 years old, females 18-50 years old * stable physical and mental health * self-report timeline follow-back (tlfb) indicating current marijuana use ≥4 days/week for ≥1 year * positive urine thc dipstick test (\> 50ng/ml; indicating marijuana use in the past 48-72 hours) * motivated to change their marijuana use (\>1 on a 10-point likert-type scale) -regular or sporadic use of nicotine cigarettes (\> 1 cigarettes in the past 30 days) -self-report of regular menstrual cycles \>6 months (female only) * willing to use double-barrier contraception if sexually active and not surgically sterilized (female only) * ability to comply with study procedures, ability to provide informed consent. exclusion criteria: * current breastfeeding (females only), * current or planned pregnancy within the next three months (females only) * dsm-iv diagnoses for psychotic disorders, bipolar disorder, adhd, major depressive disorder within the last 3 months * substance dependence within the last 3 months with the exception of nicotine and marijuana dependence * unstable psychotropic medications (\<3 months) * current use of exogenous hormones, finasteroid (propecia), efavirenz, red clover, ketoconazole and other drugs that are cyp3a4 inhibitors * conditions contraindicated to progesterone treatment (including, but not limited to, thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding disorders, heart disease, diabetes, history of stroke, allergy to peanuts, hypersensitive to progesterone and liver dysfunction)
a randomized trial of a mobile health exercise intervention for older adults with myeloid neoplasms

Conditions: Cancer; Myeloid Neoplasm

Summary: this is a phase 2 randomized controlled trial (rct) to assess the preliminary efficacy of the a mobile health exercise intervention (go-excap) versus a chemotherapy education control in 100 older patients with mn receiving outpatient chemotherapy on physical function and patient-reported outcomes (fatigue, mood, and quality of life). we will also explore the effect of the intervention on tnfα and related cytokine gene promoter methylation and their gene and protein expression.

up to 98% of older patients with myeloid neoplasms experience physical function decline, fatigue, and mood disturbances. mobile health exercise interventions are promising strategy to prevent physical function decline and improve fatigue and mood disturbances, but older patients with myeloid neoplasms receiving outpatient chemotherapy are understudied. the proposed study will investigate whether a novel mobile health exercise intervention that is adapted to this population can prevent physical function decline, improve fatigue and mood disturbances, and prevent worsening quality of life.

Eligibility criteria:
inclusion criteria: * age ≥60 years (conventional definition of older age in clinical trials of mn) * have a diagnosis of mn * planned for or receiving outpatient cancer-directed treatments (participants receiving consolidative or maintenance outpatient therapies after induction chemotherapy are allowed to enroll) * english speaking * eastern cooperative oncology group (ecog) performance status of 0-3 * no medical contraindications for exercise per oncologist * able to walk 4 meters as part of short physical performance battery measured walk (with or without assistive device) * able to provide informed consent exclusion criteria: * physical, psychological, or social impairments that would interfere with subject's ability to participate in the study or participate in the intervention, as determined by the pi or the treating team

Keywords: mobile health exercise intervention myeloid neoplasm go-excap
effectiveness analysis of ultrasound-guided intratissue percutaneous electrolysis (epi) in patient with chronic low back pain

Conditions: Chronic Low-back Pain

Summary: the main objective of this study is to analyze the effectiveness of the lumbar nerve root stimulation with ultrasound-guided percutaneous electrolysis versus the electrical dry needling of trigger points in patients with chronic low back pain.

given that recently the effectiveness of intratissue percutaneous electrolysis (epi) has become of interest in the treatment of chronic musculoskeletal pain, when conventional physiotherapy management is not successful, the epi can promote the healing biological processes. several studies have demonstrated that inflammation can play an important role in the progression of muscle degeneration, in addition to potentially contributing to painful symptoms in individuals with chronic low back pain. this technique involves nonthermal, electrochemical ablation of the lesion via the use of a cathodic fluid. the inflammation provoked is very localized and healing is rapid. although epi has been widely employed lately, the literature contains few studies validating its use. the good results reported in studies of tendinopathies have to the undertaking of the present work, which compares the long-term effectiveness of epi and dry needling-both ultrasound-guided-for the treatment of chronic low back pain. a double blind clinical trial will be developed in a sample of 80 subjects with chronic low back pain. patients of experimental group will receive 1 weekly sessions of intratissue percutaneous electrolysis for 3 weeks, for a total of 3 sessions. the aim is to compare the effectiveness of applying percutaneous electrolysis in the lumbar nerve root versus applying electrical dry needling on trigger points of the gluteus medius, quadratus lumborum, and erector spinae muscles (6 sessions, once a week) on disability, pain, fear of movement, quality of life, resistance of the trunk flexors, lumbar mobility and muscular electrical activity.

Eligibility criteria:
inclusion criteria: * low back pain ≥ 3 months. * age between 30 and 67 years old. * score ≥ 4 points on the roland morris disability questionnaire. * not being receiving other physical therapy. exclusion criteria: * presence of lumbar stenosis. * diagnosis of spondylolisthesis. * diagnosis of fibromyalgia. * treatment with corticosteroids or oral medication in recent weeks. * history of spine surgery. * contraindication of analgesic electrical therapy. * have previously received a treatment of intratissue percutaneous electrolysis. * central or peripheral nervous system disease.

Keywords: intratissue percutaneous electrolysis trigger points lumbar nerve root randomized clinical trial electrical dry needling
artificial intelligence analysis for magnetic resonance imaging in screening and diagnosis of breast cancer

Conditions: Breast Neoplasms; Magnetic Resonance Imaging

Summary: use convolutional neural networks analysis for classification of contrast-enhancing lesions at multiparametric breast mri. build an abbreviated protocal, and investigate whether an abbreviated protocol was suitable for breast magnetic resonance imaging screening for breast mass in chinese women, which can shorten the examination time and avoid enhanced imaging while ensuring the accuracy of the diagnosis.


Eligibility criteria:
inclusion criteria: * patients with clinical symptoms (define as palpable mass, nipple discharge, asymmetric thickening or nodules, and abnormal skin changes) * patients undergoing full sequence bmri examination * through the follow-up database, at least 6 months of follow-up results can be obtained to determine whether the diagnosis result is negative/benign/malignant; for patients who need pathological biopsy, the pathological biopsy results shall prevail to determine the lesion benign/malignant exclusion criteria: * the breast had received radiotherapy, chemotherapy, biology and other treatments before bmri. * there are contraindications for breast-enhanced mri examinations such as allergy to contrast agents. * a prosthesis is implanted in the affected breast. * patients during lactation or pregnancy

Keywords: breast neoplasms magnetic resonance imaging screening deep learning machine learning
clinical significance of circmettl9 gene in traumatic brain injury

Conditions: TBI (Traumatic Brain Injury)

Summary: objective: the relevance of circmettl9 to the degree of injury, disturbance of consciousness, cognitive function and prognosis in patients with moderate to severe traumatic brain injury (tbi) remains unknown. the purpose of this study was to investigate the effect of circmettl9 on the degree of injury, disturbance of consciousness, cognitive function and prognosis after tbi.

1. collect blood samples from patients with moderate to severe tbi and healthy people, and detect the expression of circmettl9 by real-time quantitative pcr detecting system(qpcr).receiver operating characteristic curve (roc) was used to analyze the sensitivity and specificity of circmettl9 in tbi patients. 2. using the glasgow coma scale (gcs) and the coma recovery scale-revised (crs-r) to assess the patient's disturbance of consciousness at 1, 3, 7, 14, and 21 days after tbi, respectively, the cognitive function of patients was assessed with the revised rachel los amigos scale-revised (rlas-r), and the correlation of circmettl9 with disturbance of consciousness and cognitive function in tbi patients was analyzed. 3. six months after tbi, the disability rating scale (drs) and glasgow outcome scale-extended (gose) were used to evaluate the prognosis of patients six months after discharge, and the correlation between circmettl9 and prognosis was analyzed. sex.

Eligibility criteria:
inclusion criteria: 1. age from 18 to 80 years old, gender is not limited; 2. have a clear history of tbi and be diagnosed by head ct, and it is the first episode; 3. glasgow coma scale (gcs) score less than or equal to 12; 4. the condition is relatively stable, and there is no serious chronic disease; 5. obtain informed consent from patients and (or) their families. exclusion criteria: 1 combined with severe underlying diseases such as respiratory failure, heart failure, liver and kidney insufficiency; previous stroke, intracranial tumor, intracranial infection, dementia, alzheimer's disease, parkinson's disease, endocrine disease, immune and blood system diseases. 2. patients with pelvic fractures, substantial organ damage, etc., which may seriously affect the treatment effect at the time of injury;

Keywords: traumatic brain injury circmettl9
az, mz, and the pulmonary system response to hypoxia

Conditions: Altitude Sickness; Hypertension, Pulmonary

Summary: the purpose of this proposal is to compare the physiological effects of acetazolamide (az) and methazolamide (mz) on the control of breathing and hypoxic pulmonary vasoconstriction. the first objective is to assess the effects of az and mz on the control of breathing in normoxia and hypoxia. to achieve this the ventilatory interaction between oxygen and carbon dioxide will be measured and effects compared between placebo, az, and mz conditions. in addition, the isocapnic and poikilocapnic hypoxic ventilatory response and hypercapnic ventilatory response will be measured with each drug. the second objective is to assess the effects of az and mz on the control of the pulmonary vasculature during hypoxia. pulmonary pressure and cardiac output will be measured during 60 minutes of poikilocapnic hypoxia.


Eligibility criteria:
inclusion criteria: * 18-40 years of age * regularly physically active * male exclusion criteria: * ex-smokers * pulmonary function \<80% of predicted * contraindications to carbonic anhydrase inhibitors (eg. severe or absolute glaucoma, adrenocortical insufficiency, hepatic insufficiency, renal insufficiency, sulfa allergy or an electrolyte imbalance such as hyperchloremic acidosis) * obese (bmi\>30kg/m2) * diuretic medication use * blood thinner use * anti-platelet drug use.

Keywords: acetazolamide methazolamide control of breathing hypoxic pulmonary vasoconstriction
use of psychotropic medications among pregnant women with bipolar disorder

Conditions: Bipolar Disorder; Pregnancy Complications

Summary: the objectives of the proposed project are: 1. to describe the patterns of mood stabilizer, antipsychotic, antidepressant, and anxiolytic prescriptions during pregnancy over a period of 12 years (2002-2014) in women aged 13 to 50 years who are diagnosed with bipolar disorder in ontario. 2. to identify the factors associated with use of antipsychotics, antidepressants, and antipsychotic-antidepressant polytherapy in pregnant women diagnosed with bipolar disorder. 3. to assess the impact of antipsychotics, antidepressants, and antipsychotic-antidepressant polytherapy on the risk of maternal, neonatal, and labour and delivery outcomes in women with bipolar disorder. 4. to assess the impact of antipsychotics, antidepressants, antipsychotic-antidepressant polytherapy on psychiatric readmission rates during the early postpartum period in women with bipolar disorder.


Eligibility criteria:
inclusion criteria: women were included in our study cohort if they met at least one of the following criteria: (i) an inpatient hospitalization with a primary discharge diagnosis of bd prior to the index pregnancy; (ii) an outpatient ohip fee code for a mood disorder plus a prescription of a mood stabilizer prior to the index pregnancy (note that the outpatient ohip fee code (296) without a prescription would not have been sufficient to identify bd patients because the fee code is used concurrently used for diagnosis of unipolar depression). additionally, women were included in the study cohort if they were continuously covered for odb throughout their pregnancy, defined as having filled any provincially funded drug prescription within six months prior to conception and another either during their pregnancy or within six months after delivery. exclusion criteria: (1) women with gestational weeks less than 20 and more than 45 at delivery; (2) pregnancies with multiple overlapping records over the study time period; (3) any data with inconsistencies and duplicate records for pregnancy; (4) any woman sharing the newborn's ikn, given that we would be unable to differentiate between the two persons; (5) observations with missing birth date for the baby and the time period between the mother's admission and discharge date greater than 14 days (since we were unable to determine the conception date for these women; and (6) women who filled a treatment prescription up to 30 days prior to pregnancy and none during the period of pregnancy.very

Keywords: bipolar disorder adverse outcomes readmission polytherapy
reactogenicity, safety and immunogenicity of a tb/flu-04l tuberculosis vaccine

Conditions: Tuberculosis

Summary: the study is a single centre, phase i, double-blind, randomized, placebo-controlled trial that explored the safety and immunogenicity of 2 doses (day 1 and day 21) tb/flu-04l tuberculosis vaccine versus matched placebo in bcg-vaccinated healthy adult subjects aged 18-50 years.


Eligibility criteria:
inclusion criteria: * healthy bcg-vaccinated male or female adult 18 through 50 years of age at the enrollment visit. * literate and willing to provide written informed consent. * a signed informed consent. * capable and willing to complete diary cards and willing to return for all follow-up visits. * for females, willing to take reliable birth control measures throughout the entire period of participation in the study. exclusion criteria: * clinical, radiological (chest x-ray) or laboratory evidence of active or past tb disease. * current or past administration of anti-tb therapy. * history of contact with tb patients. * positive quantiferon-tb gold test. * bcg vaccination in less than 6 months prior to study. * practice of nasal irrigation on a regular basis within the past six months or has engaged in nasal irrigation within two weeks prior to enrollment. * recent history of frequent nose bleeds (\>5 within the past year). * clinically relevant abnormal paranasal anatomy. * recent history (within the past month) of rhino or sinus surgery, or surgery for any traumatic injury of the nose. * current or recent (within two weeks of enrollment) acute respiratory illness with or without fever. * hypersensitivity after previous administration of any vaccine. * history of chronic alcohol abuse and/or illegal drug use. * any clinically significant abnormal laboratory finding. * a positive pregnancy test for all women of childbearing potential. * administration of immunosuppressive drugs or other immune modifying drugs within 4 weeks prior to study enrollment. * acute or chronic clinically significant pulmonary disease, cardiovascular disease, gastrointestinal disease, liver disease, neurological illness, liver disease, blood disease, skin disorder, endocrine disorder, neurological illness and psychiatric disorder as determined by medical history, physical examination or clinical laboratory screening tests, which in the opinion of the investigator, might interfere with the study objectives. * history of leukemia or any other blood or solid organ cancer. * seropositive for hiv, hepatitis b surface antigen and/or hepatitis c antibodies. * receipt of antivirals, antibiotics, immunoglobulins or other blood products within 4 weeks prior to study enrollment or planned receipt of such products during the period of subject participation in the study. * participation in another clinical trial within the previous three months or planned enrollment in such a trial during the period of this study. * subjects who are, in the opinion of the investigator, at significantly increased risk of non-cooperation with requirements of the study protocol.

Keywords: vaccine influenza vector tuberculosis
treatment and/or prevention of urinary tract infections

Conditions: Cystitis; Urinary Tract Infections

Summary: the purpose of the study is to determine the effect of an investigational oral rinse in reducing uropathogens and treating uncomplicated urinary tract infections.

a 7-day treatment with a 28-day follow up has been designed as a "before and after" assessment of the clinical signs and symptoms of an uncomplicated urinary tract infection and the reduction/eradication of urinary pathogens. enrollment is targeted to achieving 20 evaluable subjects by the end of the study. after enrolling in the trial at day 0 (first day of dosing), participants will report back to the study site at days 3, 7, and 28. at day 3 or any time thereafter, worsening of symptoms and/or increases in quantitative bacteria counts will result in removal from the trial and prescription of a rescue medication, which will be selected based on microbial susceptibility testing.

Eligibility criteria:
inclusion criteria: 1. non-pregnant adult females; 2. 18 years of age or older; 3. clinical signs with one or more symptoms of a uti (e.g., dysuria, frequency, urgency, suprapubic pain) with onset of symptoms \< 72 hours prior to study entry; 4. one positive dipstick urine test positive either for leukocyte esterase or nitrates or have a urinalysis with \> 5 wbc/hpf. 5. a pre-treatment clean-catch midstream urine culture with ≥ 104 cfu/ml of a bacterial organism exclusion criteria: 1. males; 2. women who are pregnant, nursing, or not using a medically accepted, effective method of birth control; 3. three or more episodes of acute uncomplicated uti in the past 12 months; 4. known structural abnormality that would predispose the participant to reflux or urinary retention; 5. patients with evidence of factors predisposing to the development of urinary tract infections, including calculi, stricture, primary renal disease (e.g., polycystic renal disease), or neurogenic bladder; 6. patients with significant impaired immunity secondary to chemotherapy, oral corticosteroids, or hiv; 7. patients with onset of symptoms \> 72 hours prior to entry; 8. patients with a temperature ≥ 100°f, flank pain, chills, or any other manifestations suggestive of upper urinary tract infection; 9. patients with purported hypersensitivity to iodine; 10. patients with history of thyroid disease; 11. patients who received treatment with other antimicrobials within 48 hours prior to entry; 12. any significant medical or psychiatric condition that would render examination difficult or invalid or prevent the subject from active study participation; inability to use an oral rinse; 13. use of concomitant medication that, in the opinion of the study directors, might interfere with the outcome of the study.

Keywords: cystitis urinary tract infections